knowledge -WSS

knowledge

author：fashion 2025-09-30 14:09:30 - browse：91

CHICAGO — The Food and Drug Administration’s top oncologist reiterated that the agency doesn’t want drugmakers applying for approval with data from trials solely run in a single country such as China, but instead wants to see companies conducting studies across the world.

The comments by Richard Pazdur, director of the FDA’s Oncology Center of Excellence, came as more drugmakers report data from China, with Miami-based Summit Therapeutics earlier this week announcing that its investigational drug beat Merck’s blockbuster Keytruda in a head-to-head non-small cell lung cancer study in China.

It’s not a blanket policy, and the agency would assess each company’s submission to see how applicable the data are to the U.S. population, but in general, “I am pro multi-regional trials,” Pazdur said Friday at STAT@ASCO, STAT’s event at the American Society of Clinical Oncology annual meeting.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Padmanee Sharma of MD Anderson at center of lawsuit over credit

WSS

STAT wants to know your pick for a great summer read or listen

Why Novartis is going to walk from its acquisition of MorphoSys

Padmanee Sharma of MD Anderson at center of lawsuit over credit

ASCO Daily Recap: CAR

Readout LOUD: Venture capital, Gilead, and more M&A

Bernie brings in new pharma CEOs to talk drug prices

hotspot

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Apple is now the first public company to be valued at $3 trillion

The CDC's new social media misinformation war

Alkermes shareholders re

STAT wants to know your pick for a great summer read or listen

BioMarin wins approval for gene therapy to treat hemophilia A

Texas Medical Board asked to define abortion emergency exception

Hepatitis C has a cure — but many Americans still lack access to it

Why Novartis is going to walk from its acquisition of MorphoSys

What does generative AI mean for health care? We asked experts

UnitedHealth CEO's Medicaid comments send insurer stocks diving

hotspot

FDA approves Moderna’s RSV vaccine, its second licensed product

Illumina board agrees to spin off Grail, as divestment plans proceed

UnitedHealth CEO's Medicaid comments send insurer stocks diving

Anthony Fauci pushes back on GOP claims during Covid hearing

Elevance PBM president out as customers face prescription chaos

Top private equity targets in 2023: cardiology, clinical trials, lasers

focus

hotspot

entertainment

Wikipedia